Methazolamide
FDA-approved product (tablet, oral), marketed as Methazolamide, Neptazane.
- Registered studies
- 11
- Lab records
- 4
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Glaucoma
- Open-angle glaucoma
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Carbonic anhydrase inhibitors
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA27.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli19.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis85.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
11registered studies name this medicine, for any condition. See them below.
Experimental
- M. tuberculosis: measured active in 4 of 4 lab records
Show the 4 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Methazolamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance
NCT05575180 · start 2023-08-11
Registered record
- Registry ID
- NCT05575180
- Conditions
- High Altitude Effects
- Interventions
- Acetazolamide 250Mg Tab; Methazolamide Pill; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2023-08-11
- Completion
- 2024-02-22
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHigh Altitude EffectsInterventionAcetazolamide 250Mg Tab; Methazolamide Pill; PlaceboPhasePhase 4Registry statusCompletedUse of Methazolamide to Lower Intraocular Pressure
NCT05498103 · start 2023-02-17
Registered record
- Registry ID
- NCT05498103
- Conditions
- Glaucoma, Open-Angle
- Interventions
- Methazolamide 25 MG; Methazolamide 50 MG
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Active not recruiting
- Start
- 2023-02-17
- Completion
- 2024-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucoma, Open-AngleInterventionMethazolamide 25 MG; Methazolamide 50 MGPhasePhase 4Registry statusActive not recruitingComparison of Two Different Sedation Protocols During Transvaginal Oocyte Retrieval
NCT03362021 · start 2018-01-05
Registered record
- Registry ID
- NCT03362021
- Conditions
- Infertility
- Interventions
- transvaginal oocyte retrieval
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2018-01-05
- Completion
- 2019-11-20
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfertilityInterventiontransvaginal oocyte retrievalPhaseNot recordedRegistry statusTerminatedMuscle Fatigue and Carbonic Anhydrase Inhibitors
NCT02758470 · start 2016-11
Registered record
- Registry ID
- NCT02758470
- Conditions
- Hypoxia
- Interventions
- Acetazolamide; Methazolamide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-11
- Completion
- 2017-06-30
- Enrolment
- 13
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHypoxiaInterventionAcetazolamide; Methazolamide; PlaceboPhasePhase 4Registry statusCompletedAZ, MZ, and the Pulmonary System Response to Hypoxia
NCT02760121 · start 2016-05
Registered record
- Registry ID
- NCT02760121
- Conditions
- Altitude Sickness; Hypertension, Pulmonary
- Interventions
- Acetazolamide; Methazolamide; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-05
- Completion
- 2016-08
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAltitude Sickness; Hypertension, PulmonaryInterventionAcetazolamide; Methazolamide; PlaceboPhasePhase 4Registry statusCompletedAcamprosate and Methazolamide for Essential Tremor
NCT06312800 · start 2016-03
Registered record
- Registry ID
- NCT06312800
- Conditions
- Essential Tremor
- Interventions
- Acamprosate; Placebo; Methazolamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2016-03
- Completion
- 2017-12
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEssential TremorInterventionAcamprosate; Placebo; MethazolamidePhasePhase 2Registry statusWithdrawnStop Retinal Ganglion Cell Dysfunction Study
NCT02390284 · start 2015-09
Registered record
- Registry ID
- NCT02390284
- Conditions
- Glaucoma
- Interventions
- Latanoprost; Bimatoprost; Travoprost; Timolol; Dorzolamide; Brinzolamide; Acetazolamide; Methazolamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2015-09
- Completion
- 2024-10-04
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGlaucomaInterventionLatanoprost; Bimatoprost; Travoprost; Timolol +4 morePhasePhase 3Registry statusTerminatedThree New Ideas to Protect Special Forces From the Stress of High Altitude
NCT02463357 · start 2015-08
Registered record
- Registry ID
- NCT02463357
- Conditions
- Mountain Sickness
- Interventions
- Quercetin; Nifedipine extended release; Methazolamide; Metformin; Placebo; Nitrite
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2015-08
- Completion
- 2016-09
- Enrolment
- 148
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMountain SicknessInterventionQuercetin; Nifedipine extended release; Methazolamide; Metformin +2 morePhasePhase 4Registry statusCompletedRapid Acclimatization to Hypoxia at Altitude
NCT01702025 · start 2012-06
Registered record
- Registry ID
- NCT01702025
- Conditions
- Physiological Function in Low Oxygen Environment
- Interventions
- Placebo; Aminophylline; Methazolamide; Aminophylline+Methazolamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2012-12
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPhysiological Function in Low Oxygen EnvironmentInterventionPlacebo; Aminophylline; Methazolamide; Aminophylline+MethazolamidePhasePhase 1 / Phase 2Registry statusCompletedSafety Evaluation of Aminophylline and Methazolamide
NCT01587027 · start 2011-12
Registered record
- Registry ID
- NCT01587027
- Conditions
- Mountain Sickness
- Interventions
- Aminophylline; Methazolamide; Aminophylline and Methazolamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-12
- Completion
- 2012-02
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMountain SicknessInterventionAminophylline; Methazolamide; Aminophylline and MethazolamidePhasePhase 1Registry statusCompletedImproving Tumor Oxygenation in Cervical Cancer
NCT00257829 · start 2004-07
Registered record
- Registry ID
- NCT00257829
- Conditions
- Cervical Cancer
- Interventions
- Methazolamide; Cisplatin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Withdrawn
- Start
- 2004-07
- Completion
- 2006-09-20
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCervical CancerInterventionMethazolamide; CisplatinPhasePhase 2Registry statusWithdrawn